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SUMMARY 
 
   Purpose: To evaluate results of postoperative radiotherapy (PRT) for Low-Grade Gliomas (LGG).  
   Material/Methods: Between 1985 and 1995, 158 patients with LGG (WHO II) received PRT. 
A multivariate analysis for possible prognostic factors was performed. CT scans taken prior to surgery 
and at the time of recurrence were compared to define the recurrence pattern in relation to initial 
tumour site and the irradiated volume. 
   Results: Ten-year overall and progression free survival rates were 41% and 29%, respectively. 
A multivariate analysis revealed that good WHO performance status, seizures at presentation, 
duration of symptoms before treatment >12 months, age <45 years and gross total resection were 
associated with increased survival. All but three analysed recurrences occurred within the initial 
tumour sites. There was only one case of recurrence outside the previously irradiated volume.       
   Conclusions: Long-term treatment results were unfavourable for most LGG patients. Our data 
confirm the prognostic value of the above-mentioned factors. 
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INTRODUCTION 
 
   Despite relatively good clinical progno-
sis, Grade II WHO Low-Grade Gliomas 
(LGG) diffusely infiltrate surrounding brain 
structures and show in their natural history 
a tendency towards progression of ma-
lignancy by increasing anaplasia [1]. 
Management of such tumours, especially 
the use of immediate postoperative 
radiotherapy (PRT), is a subject of many 
controversies. Some authors show a posi-
tive impact of PRT on survival in retros-
pective studies [2,3,4,5,6,7]. Others report 
no difference in survival between patients 
(pts) irradiated immediately after surgery 
and those for whom radiotherapy was 
delayed until tumour progression [8,9,10, 
11]. Recently conducted randomized stu-
dies have tried to define a real place 
of PRT in management of LGG. These 
first results showed that the increase 
of doses from 45 to 59.4 Gy and from 50.4  
 
 
 
to 64.8 Gy did not improve the survival 
[12,13]. This finding has led many authors 
to the conclusion on the inefficacy of PRT 
in LGG. By contrast, others like Rudoler 
et al. [14] emphasize the strictly local site 
of failure in LGG as a need for PRT and 
consider the doses employed as inade-
quate, probably too low for LGG. Although 
the principle of limiting the irradiated 
volume to a tumour with 2 cm margins 
in LGG is not questionable, studies 
concerning the pattern of failure in LGG 
are relatively scarce and are mainly limited 
to small groups of patients [15,6,10,16, 
14,17]. The high percentage of local 
failures in the range of doses of 45-65 Gy 
leads to a question whether or not dose 
escalation within the primary tumour site 
using new techniques such a brachythe-
rapy, conformal radiotherapy or radiosur-
gery can improve the therapeutic ratio. 
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   We report treatment results, and progno-
stic factors  in 158 pts with LGG treated 
with PRT at one institution over 10 years. 
Based on our experience we have also 
made an attempt to determine the pattern 
of recurrence with a view to finding a be-
tter definition of the appropriate volume 
to irradiate and possible future design 
for a dose escalation study.      
 
MATERIALS 
 
   The records of 158 patients with WHO 
Grade II LGG treated with PRT at our insti-
tution between 1985 and 1995 were revie-
wed retrospectively. The characteristics 
of the patients and their treatment are 
summarised in Table 1. Radiotherapy star-
ted 2-20 weeks (median: 5 weeks) after 
surgery. For 7 pts it was a second surgery 
for LGG, they had been referred to strict 
observation after the first tumour resec-
tion. All patients were irradiated with 
curative intent. Total doses ranged from 
44.0 to 66.0 Gy (median: 57.6 Gy). Doses 
per fraction were 1.8 – 2.0 Gy, three pts 
received 3.0 Gy per fraction during the first 
part (to 30.0 Gy) of their treatment due 
to initial poor performance status. High 
energy photons (Co60 or X 4 MV, 9 MV, 
15 MV) were used in all pts. The tumour 
with 2-3 cm margins was irradiated 
in 126 (80%) pts, in 27 (17%) pts 
the whole brain was treated by a dose 
of 44.0-50.0 Gy with subsequent irra-
diation of the tumour with 2 cm margins 
by 56.0-60.0 Gy. Five (3%) pts had 
exclusively whole brain irradiation. A 2-D 
planning system Mevaplan was used 
in most patients, 3-D treatment planning 
system was not available. All patients 
were followed up clinically and had CT 
or MRI examinations every 3 months 
during the first 3 years, then every 
6 months.  
 
 
 
Tab. 1. Characteristics of 158 LGG patients treated with postoperative radiotherapy between 1985-1995. 
AGE Median /Mean 
Range 
39  / 40 years 
17-74 years 
SEX Female : Male 62 (39%) : 96 (61%) 
PERFORMANCE STATUS  
 
 Grade  0 
             1 
             2 
             3  
             4 
2     pts.   (1%) 
106  ‘’      (67%) 
33    ‘’      (21%) 
14    ‘’      (9%)  
3      ‘’      (2%)  
NEUROLOGIC STATUS 
BEFORE RADIOTHERAPY  
Grade   1 
             2 
             3 
             4 
61   pts.   (39%) 
34     ‘’     (21,5%) 
39     ‘’     (24,5%) 
24     ‘’     (15%) 
SEIZURES BEFORE TREATMENT Present 
Absent 
124    pts.    (78%) 
34       ‘’       (22%) 
DURATION OF SYMPTOMS 
BEFORE INITIAL SURGERY 
Median / Mean 
Range 
8  / 26  months 
1-190      ‘’    
TIMING OF  RADIOTHERAPY Delayed until progression 
Immediate after surgery 
7       pts.  (4%) 
151   ‘’      (96%) 
 HISTOLOGY Astrocytoma 
-  Fibrillary 
-  Protoplasmic 
116  pts.  (73%) 
   - 50 (43%  astrocytomas) 
   - 8   (7%        ‘’                ) 
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- Gemistocytic 
- Non classified and mixed 
Oligodendroglioma 
Mixed glioma 
   - 26 (22%      ‘’               ) 
   - 32 (28%      ‘’               ) 
25   pts.     (16%) 
17    ‘’        (11%) 
LOCATION Frontal 
Temporal 
Parietal 
Occipital 
2-3 lobes 
Infratentorial 
47      pts.  (30%) 
34      ‘’      (22%) 
12      ‘’      (8%) 
2        ‘’      (1%) 
56      ‘’      (35%) 
7        ‘’      (4%) 
SIZE OF TUMOUR BEFORE 
SURGERY 
To 3 cm 
> 3 and ≤ 5cm 
> 5 cm 
No data 
24    pts.      (15,0%) 
48 ‘’        (30,5%) 
65     ‘’         (41.0%)  
21   ‘’         (13.5%)  
SIZE OF TUMOUR BEFORE 
RADIOTHERAPY 
No tumour detected 
To 3 cm 
> 3cm and  ≤ 5cm 
> 5 cm 
No data 
39    pts.    (25%) 
40     ‘’       (25%) 
14     ‘’       (9%)  
15     ‘’       (9%) 
50     ‘’       (32%) 
T STAGE  T1 
T2  
T3 
T4 
49   pts.       (31,0%) 
17 ‘’         (11,0%) 
18 ‘’         (41,5%) 
24           ‘’        (16,5%) 
PRESENCE OF CALCIFICATIONS 
IN TUMOUR 
Yes / No 
No data 
20 / 114  pts. (12,5%)/ (73%)        
24         ‘’         (14,5% 
TUMOUR ENHANCEMENT 
IN CT OR MRI SCANS 
Yes 
No  
No data 
40   pts. (25,0%) 
70    ‘’ (44,5%) 
48    ‘’  (30,5%) 
EXTENT OF RESECTION Total 
Subtotal 
Partial/Biopsy 
39      pts. (25%) 
32        ‘’ (20%) 
73/14   ‘’  (46%) / (9%) 
 
  
METHODS 
 
   The overall survival and survival without 
progression were estimated according 
to the Kaplan-Meier method. Both types 
of survival were calculated from the first 
day of PRT. Progression was defined 
as any relapse in case of complete 
remission after surgery followed by PRT, 
or any increase in the size of the residual 
tumour, or appearance of the mass effect 
or/and contrast enhancement in the earlier 
non-enhancing tumour. The influence on 
the overall survival of all known prognostic 
factors was estimated using a univariate 
analysis (UA) with a log-rank test. The fol-
lowing variables were included in the UA: 
age, sex, performance status, neurologic 
status before radiotherapy estimated retro-
spectively according to the EORTC/MRC 
scale (app. 1) [18], presence of seizures 
before treatment, mental changes, dura-
tion of symptoms before diagnosis, tumour 
location, histology, T stage according 
to the UICC classification (app. 2) [19], 
the size of tumour before surgery, the size 
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of tumour before radiotherapy, presence 
of calcifications in the tumour, contrast 
enhancement in initial CT or MRI scans, 
the extent of tumour resection, immediate 
versus delayed radiotherapy, the irradiated 
volume, total dose and the tumour respon-
se to radiotherapy. Factors influencing 
survival with the statistical significance 
of p<0.2 in the UA for which there were no 
missing data were included in the multi-
variate Cox-regression analysis (MA) 
for final estimation of prognostic signify-
cance. All data were analyzed using 
the STATISTICA PL (1999) statistical soft-
ware. In pts with progression and with all 
radiological data available (initial and tho-
se from recurrence) the pattern of failure 
was analysed. CT scans taken prior to ini-
tial surgery and at the time of recurrence 
have been compared to define the recur-
rence pattern in relation to the initial 
tumour site and to the irradiated volume. 
According to the available radiological 
data the initial and recurrent tumours were 
drawn in the simulator films. Differences 
in scale between scans and the simulator 
films and differences in head position were 
taken into account. If there was any doubt 
as to the location of the recurrent or initial 
tumour a second opinion of a radiologist 
was sought.   
 
RESULTS 
 
   Treatment outcome: With a median fol-
low-up of 79 months for a living patient 
(range:52-167 months) 96 of 158 pts rela-
psed. The median time to progression was 
50 months. Eighty-five pts died of progre-
ssive tumour and four from an intercurrent 
disease. Five pts (2 with, 3 without progre-
ssion) were lost from the follow-up bet-
ween 45 and 124 months. The 3-, 5-, and 
10-year actuarial overall survival percen-
tages were 68-, 55, and 41%, respectively 
(fig. 1). The 3-, 5-, and 10-year actuarial 
progression free survival percentages 
were 59-, 48-, and 29%, respectively 
(fig. 2). In 78 (49%) pts with residual 
tumour visualised on CT or MRI scans 
made after surgery and before radio-
therapy precise estimation of response 
to radiotherapy was possible. There were 
51 (65.5%) complete responses, 9 (11.5%) 
partial responses, 9 (11.5%) no changes, 
and 9 (11.5%) progressions. Of 60 pts 
with response to radiotherapy, 75% 
responded within the first 3 months after  
PRT, in 25% of cases responses were 
delayed from 6 to 26 months.  
   Prognostic factors: The univariate ana-
lysis (UA) showed that the overall survival 
was increased by the following factors: 
a better WHO performance status 
(p<0.00001) (fig. 3), complete tumour re-
gression after radiotherapy following 
surgery (p<0.00001), seizures at presen-
tation (p=0.00005) (fig. 4), age under 
45 years (p=0.0002), size of tumour before 
radiotherapy ≤ 3 cm (p=0.0006), duration 
of symptoms before diagnosis ≥12 months 
(p=0.0007), better neurologic status 
according to EORTC/MRC scale 
(p=0.003), T1/T2 stage of the tumour 
according to the UICC classification 
(p=0.003), histology of oligodendroglioma 
or mixed glioma (p=0.004) (fig. 5), total 
or subtotal resection (p=0.009) (fig. 6), 
no contrast enhancement in initial CT or 
MRI scans (p=0.02), and the size of tu-
mour before surgery ≤ 3 cm (p=0.03). 
Sex, mental changes, presence of cal-
cifications, tumour location, immediate 
versus delayed radiotherapy, total radia-
tion dose, irradiation volume (tumour with 
margins exclusively versus whole brain 
irradiation) did not influence the overall 
survival. There was no difference in sur-
vival between different subtypes of astro-
cytoma; in particular gemistocytic astro-
cytoma did not worsen the survival. 
   The multivariate analysis (MA) retained 
only seizures at presentation, performance 
status, duration of symptoms before dia-
gnosis, age, extent of resection as progno-
stic factors for the overall survival. Patients 
with oligodendroglioma showed better 
survival at the limits of statistical signif-
icance (table 2). Unfortunately, the highly 
significant in UA response to treatment 
evaluated after radiotherapy and the pre-
sence of contrast enhancement could 
not  be included in the MA due to missing 
data.  
   Toxicity of PRT: Acute side effects 
were evaluated in the whole group, whe-
reas late effects were considered in 145 
(92%) pts. Acute toxicity was minor, only 
in 8 (5%) pts prolongation of the treatment 
time beyond 5 days was required because  
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Fig. 1. Overall survival in 158 patients treated with PRT.
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Fig. 2. Progression free survival in 158 patients treated with PRT.  
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Fig. 3. Overall survival according to WHO performance status. 
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Fig. 4. Overall survival according to presence of seizures before diagnosis.  
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Fig. 5. Overall survival according to histology (ASTRO - astrocytoma, OLIGO - oligodendroglioma and mixed glioma).
 
TOT/SUBTOT     
PART/BIOPSY    
 Completed Censored 
Time [months]
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
0 20 40 60 80 100 120 140 160 180 200
Fig. 6. Overall survival according to extent of resection (TOT/SUBTOT - total and subtotal resections, PART/BIOPSY
- partial resections and biopsies).  
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Tab. 2. Prognostic factors influencing overall survival in  multivariate analysis.  
 
VARIABLE RELATIVE RISK OF DEATH 
95% CONFIDENCE 
INTERVAL  P-VALUE 
Seizures before treatment 
Yes 
No 
 
 
1,00 
2,60 
 
 
1,61-4,19 
 
 
0,00001 
Performance status  
0-1 
2-4 
 
0,41 
1,00 
 
0,26-0,64 
 
0,0001 
Duration of symptoms 
before diagnosis 
≤ 1 year 
> 1 year 
 
 
2,39 
1,00 
 
 
1,49-3,89 
 
 
0,0003 
Age 
< 45 years 
≥ 45 years 
 
1,00 
1,50 
 
1,19-1,90 
 
0,0007 
Extent of resection 
Total or subtotal 
Partial or biopsy 
 
1,00 
1,64 
 
1,04-2,61 
 
0,03 
Histology 
Astrocytoma 
Oligodendroglioma 
or mixed glioma 
 
1,79 
1,00 
 
1,01-3,19 
 
0,05 
Neurologic status before 
radiotherapy 
Without deficits (1) 
With deficits (2-4) 
 
 
0,73 
1,00 
 
 
0,17-1,29 
 
 
 
0,28 
Stage T  
T3-T4 
T1-T2 
 
1,14 
1,00 
 
0,60-1,64 
 
0,61 
 
Appendix No 1.  
EORTC/MRC Neurologic Deficits Score [18]. 
1. absence of any neurologic deficit detectable 
2. minor neurologic deficits; without any impairment of normal activity 
3. neurologic deficits leading to some impairment of normal activity (paresis, minor mental changes) 
4. serious neurologic deficits leading to disability to care for himself: paralysis, aphasia, serious mental (emotional 
and/or cognitive) changes.  
5. any communication with patient impossible 
 
Appendix No 2. 
UICC TNM tumour staging classification for supratentorial brain gliomas [19] 
T1 – Greatest diameter ≤ 5 cm, located unilaterally 
T2 - Greatest diameter >5 cm, but not encroaching on the ventricles or crossing the midline 
T3 – Any size, definitely encroaching on the ventricular system, but not crossing the midline 
T4 – Crossing the midline or the tentorium 
 
of CNS (6 pts) or skin toxicity. Ninety-nine 
(63%) pts had no radiological or clinical 
signs of late toxicity. Forty-six (37%) pts 
had minor late toxicity: 18 pts had only 
radiological abnormalities (hypodensity 
in the white matter, cortical atrophy, calci-
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fications), 20 pts showed only clinical 
symptoms (impairment in mental and/or 
affective functioning), and 8 pts had both 
radiological and clinical symptoms. There 
was no case of major toxicity such as ra-
dionecrosis. 
   Failure patterns: Histology of recur-
rence was determined in 24 of 96 pro-
gressions. There were 8 cases with initial 
histology, 10 with WHO Grade III gliomas, 
and 6 with WHO Grade IV gliomas (glio-
blastoma). Thus, malignant transformation 
was confirmed in 67% of cases. Of 72 re-
currences with unknown histology there 
were 57 (79%) radiological images sug-
gesting malignant transformation (butterfly 
glioma or evident contrast enhancement 
in earlier nonenhancing tumour).  
   Localisation of recurrence in relation 
to the initial tumour site and the irradiation 
volume was possible in 73 of 96 cases. 
In these 73 pts, all radiological data from 
the initial tumour presentation and from 
recurrence and simulator films showing 
irradiation fields were available. As des-
cribed above, original and recurrent 
tumours were drawn in the simulator films. 
Recurrences were located in 97.5% of ca-
ses at the initial site and all but one within 
the irradiation volume. More precisely, four 
types of recurrences were found: (1) sixty-
six recurrences at the initial tumour site 
and apparently within the irradiation vo-
lume, (2) two recurrences outside the ini-
tial tumour, but within irradiation volume, 
(3) four recurrences at the initial tumour 
site with dissemination outside the irra-
diation volume, and (4) one recurrence 
outside the irradiation volume. This latter 
case is not clear, because the second 
tumour occurred in the controlateral hemi-
sphere 6 years after the initial treatment 
for WHO III astrocytoma and could also 
have been a second primary.        
 
 
DISCUSSION 
 
   With a median follow-up of 79 months, 
which seems sufficient for LGG, the re-
sults concerning the overall and progre-
ssion free survival are in accordance with 
other data from computerised tomography 
era. The five-year survival in patients with 
LGG treated since the 1980s ranged 
from 50% to 80% [8,20,12,9,21,22,23,10, 
14,24].  
   The strongest prognostic impact of sei-
zures is one of the most interesting fin-
dings in our study. Improvement of sur-
vival with seizures at presentation in LGG 
have also been reported by others [25,8, 
9,11]. In contrast, some authors point out 
that epilepsy as a presenting symptom is 
related to a smaller tumour volume and 
thus leads to a selection of cases for early 
diagnosis [10,26]. The prevalence of sei-
zures decreases significantly with incre-
asing histological grade of gliomas. 
Epilepsy is considered to be a marker 
for less aggressive tumour biology within 
the high-grade [26]. In our study, the pre-
sence of seizures was not correlated 
either with a smaller tumour size or with 
a shorter duration of symptoms before 
diagnosis. Thus, seizures remained really 
the strongest independent prognostic 
factor, possibly related to the inherent less 
aggressive biological behaviour of the tu-
mour. 
   Like other data [8,9,21,23,14,27] in our 
study the WHO performance status 
appeared to be a better predictor than 
the neurologic status. The performance 
status depends strictly on the presence 
of neurologic deficits. Therefore, some 
authors claim that the use of a neuro-
logical performance scale instead 
of the performance status scores improves 
the stratification of patients with brain 
tumours for clinical trials [12, 28]. In our 
study, the retrospective use of the neuro-
logic performance score could have been 
to some extent subjective and inappro-
priate.  
   The longer duration of symptoms before 
diagnosis, characterising more indolent 
behaviour of tumours especially in older 
reports was considered to be a factor 
related to improved survival [29]. More 
recent studies have usually included pts 
with a short duration of symptoms, beca-
use of rapid implementation of diagnostic 
tools, so this factor has been loosing its 
predictive value [30]. Our group of patients 
was very heterogeneous with respect 
to this variable. The duration of symptoms 
ranged from 1 to 190 months. Therefore, 
it was possible to show its prognostic 
importance.   
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   Age is not a questionable prognostic 
factor for primary brain tumours. However, 
for statistical purposes the finding 
of an optimal cut point differentiating 
between two prognostic subgroups 
remains a problem. Some authors report 
that even at the early age of 30-35 years 
the survival of pts with LGG rapidly 
decreases [32,33]. For others, 40 or 50 
years is an optimal cut point differentiating 
between two prognostic groups [6,8,9,10, 
31,21]. We found 45 years to be a cut 
point after having tested various values 
and then selecting the one giving the mi-
nimum P-value. We have also tested age 
as a continuous parameter in the MA and 
we found similar results. According 
to Recht et al. [34], in pts >45 years of age 
the observation strategy of non-enhancing 
lesions is not safe because of rapid 
increase in anaplasia. The increased risk 
of finding malignancy in primarily dia-
gnosed LGG in pts >45 years of age may 
explain the poorer prognosis with age 
in such tumours [35]. 
   The extent of resection as a prognostic 
factor is more questionable, particularly 
if it is based exclusively on the opinion 
of a surgeon. The extent of resection esti-
mated by a surgeon often loses its pro-
gnostic value [8, 28, 21, 24]. Although our 
estimation of resection was based on 
the neurosurgeon’s opinion, we found 
a statistically significant difference 
in the survival between pts with total and 
subtotal resections and those with partial 
resections and biopsies. Similar results 
concerning this variable based only on 
the neurosurgeon’s opinion are reported 
by others [20,31,10,36,17,29]. As shown 
in the UA the improvement in treatment 
results with a smaller tumour size after 
surgery additionally reinforces the opinion 
about the positive influence of surgical 
tumour sterilization on survival. 
   Improved survival of pts with an oligo-
dendroglial component in brain gliomas 
as compared with those with pure astro-
cytomas has been largely reported [37,9, 
23,17,27]. In some reports no such diffe-
rence has been found. This may be the re-
sult of differences between various cen-
ters of the definition of oligodendroglioma 
and particularly of mixed gliomas. No wor-
se survival in gemistocytic astrocytomas 
in our study is in disagreement with most 
studies [33,38]. This may be due to the 
high percentage of non-classified astrocy-
tomas (28%) which may have contained 
tumours with a gemistocytic component. 
Some authors indicate a rapid malignant 
progression of this type of LGG and some 
others include gemistocytic astrocytomas 
in grade III of malignancy [38].     
   Seven pts with radiotherapy delayed 
until recurrence had the same survival 
as 151 pts with immediate radiotherapy, 
which, according to some authors, suggest 
no indication for immediate PRT. A small 
number of pts with delayed radiotherapy, 
as well as the retrospective character 
of the study did not allow us to draw any 
conclusions about the optimal time for the 
implementation of radiotherapy in LGG. 
This problem has been studied in a ran-
domized EORTC trial no 22845. Prelimi-
nary results show inferior progression free 
survival in pts with delayed radiotherapy 
as compared with those immediately 
irradiated [39].  
   The percentage of malignant transfor-
mation of recurrences amounting to 70% 
in our study is similar to other reports [40]. 
The study concerning the localization 
of recurrences included 73 pts and  was 
the largest one among those dealing with 
this problem [15,10,16,14,29]. However, 
there are two possible pitfalls in the me-
thodology. One is that the study of the pat-
tern of failures was conducted by one 
investigator and only in case of serious 
doubt a second opinion was sought. 
The differences in the definition of targets 
in treatment planning are well known [41]. 
The risk of committing errors in a complex 
procedure such as tracing projections 
of tumours from CT scans to simulator 
films could have been additionally exacer-
bated. Another possible pitfall in this study 
was the lack of relation to a 3-D- planning 
system. The localisation of relapse within 
the radiation field visualised on a simulator 
film does not necessarily indicate a real 
occurrence of failure within the area 
of the prescribed dose. Therefore, recur-
rences in the fall-off dose area could have 
been missed and considered as total dose 
failures. Despite these two limitations 
in our study, by taking into account the lar-
ge size of the group and collective deci-
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sions in case of doubt, we think that re-
currences in LGG were closely related 
to the initial tumour site and the irradiation 
volume. 
   The high percentage of strictly local 
failures as well as the improvement 
in survival with sterilization of the tumour 
(a larger extent of resection, complete res-
ponse on combined treatment) suggest 
a need for intensification of local treat-
ment. Limitations of surgery due to many 
tumour locations and the infiltrating type 
of the growth are well known. More inten-
sive use of new methods of radiotherapy 
such as conformal or stereotactic tech-
niques opens us prospects for future stu-
dies. 
 
 
CONCLUSIONS 
 
- Ten-year actuarial progression free sur-
vival in 29% of patients is a proof of low 
long-term efficacy of surgery followed 
by radiotherapy using doses of 44-66 Gy 
in management of LGG. 
- The prognostic factors such as: seizures, 
performance status, symptom duration, 
age and extent of surgery should be 
taken into account in therapeutic deci-
sions and planning of clinical studies 
in LGG. 
- Localisation of failures in all but one 
patient within the irradiation field is 
a proof of the low effectiveness of ra-
diotherapy using conventional techni-
ques and doses. Thus, intensification 
of local treatment is needed. 
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